Abstract
Rituximab (the chimeric anti-CD20 antibody) is widely used in the treatment of CD20 positive non-Hodgkin’s lymphoma (NHL). The response rate at relapse after repeated use in prior CD20 positive responders is lower than 50%. Several mechanisms can be responsible for rituximab resistance. CD20 negative relapses which transformed from CD20 positive aggressive and indolent forms of lymphoma can be the one of the reason of secondary resistance to rituximab. The authors report a case with combination of aggressive and indolent form of lymphoma who relapsed after 7 months from the last dose of rituximab therapy. CD20 transformed negative from positive in her relapsed disease. Patients with CD20 positive B cell NHL must rebiopsy after first line rituximab therapy if their disease relapsed or progressed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–68.
Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czucman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135–43.
Kinoshita T, Nagai H, Murate T, Saito H. CD20 negative relapse in B-cell lymphoma after treatment with rituximab. J Clin Oncol. 1998;16:3916.
Grillo-Lopez AJ, Kunkel L. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin Cancer Res. 2000;6:317–8.
Schmitz K, Brugger W, Weis B, Kaiserling E, Kanz L. Clonal selection of CD20 negative non Hodgkin’s lymphoma cells after treatment with anti CD20 antibody rituximab. Br J Haematol. 1999;106:571–2.
Foran JM, Norton AJ, Micallef IN, Taussıg DC, Amess JA, Rohatıner AZ, Lister TA. Loss of CD20 expression following treatment with rituximab (chimeric monoclonal chimeric anti CD20): a retrospective cohort analysis. Br J Haematol. 2001;114:881–3.
Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, Gill D. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin’s lymphoma: a retrospective review. Br J Haematol. 2002;119:412–6.
Alvaro-Naranjo T, Jaen-Martinez J, Guma-Pardro J, Bosch-Princep R, Salvado-Usach MT. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of literature. Ann Hematol. 2003;82:585–8.
Tomita A, Hiraga J, Kiyoi H, Ninomiya M, Sugimoto T, Ito M, et al. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol. 2007;86:49–57.
Terui Y, Sakurai T, Mishima Y, et al. Identification of CD20 mutations in malignant lymphoma: can they be predictors of response to rituximab? Blood. 2005;106:288–9.
Sonoki T, Li Y, Miyanishi S, Nakamine H, et al. Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab. Int J Hematol. 2009;89(3):400–2.
Berinstein N, Grillo-Lopez A, White C, BenceBruckler I, Maloney D, et al. Rituximab (ICEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 1998;9:995–1001.
Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90.
Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927–32.
Igarashi T, Itoh K, Kobayashi Y, et al. Phase II and pharmacokinetic study of rituximab with eight weekly infusions in relapsed aggressive B-cell non-Hodgkin’s lymphoma (B-NHL). Prog Proc Am Soc Clin Oncol. 2002;21:1286.
Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O’Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J, Moskowitz CH. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103(10):3684–8.
Amar-Maman D, Mounier N, Manson J, et al. Evaluation of efficacy and toxicity of rituximab plus aracytin–platinum(R-DHAP) regimen in non Hodgkin lymphoma (NHL) relapsing patients. Blood. 2002;100:293a.
Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F, Michallet AS, Traullé C, Salles G, Coiffier B. Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. Leuk Lymphoma. 2010;51(3):399–405.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Duman, B.B., Şahin, B., Ergin, M. et al. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): A case report and review of the literature. Med Oncol 29, 1223–1226 (2012). https://doi.org/10.1007/s12032-011-9955-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-011-9955-3